Clinical Trial Details
— Status: Withdrawn
Administrative data
| NCT number |
NCT05862675 |
| Other study ID # |
ChongqingMU |
| Secondary ID |
|
| Status |
Withdrawn |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
May 2, 2023 |
| Est. completion date |
May 30, 2026 |
Study information
| Verified date |
July 2023 |
| Source |
Children's Hospital of Chongqing Medical University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
Acute lung injury is a highly prevalent disease in children, posing a serious threat to their
health and causing economic burden on society and families. It has received high attention.
Blocking the cascade immune inflammatory response that occurs in the respiratory tract and
finding key targets for the prevention and treatment of acute lung injury has become an
important challenge faced by the medical community. The pathogenesis of acute lung injury is
complex, involving the combined action of multiple cells and cytokines in the immune system.
Therefore, it is necessary to further study the function of immune cells and specific immune
pathogenesis, providing new ideas and theoretical basis for clinical treatment of acute lung
injury. The omics technology includes Genomics, Transcriptome, proteomics, metabolomics, etc.
Through qualitative and quantitative analysis of changes in low molecular weight molecules or
metabolites of biological samples, it provides a new way to find biomarkers and pathogenesis.
We plan to study the peripheral blood of children with acute lung injury and healthy
children, and use network analysis to screen for differential genes and related enrichment
pathways in acute lung injury. We aim to explore the correlation between immune regulation
and inflammatory repair in children with acute lung injury, and analyze the regulatory
mechanisms between immune cells related to it. Provide assistance for clinical diagnosis and
treatment.
Description:
1. Inclusion criteria of the test group: (1) Meeting the specific diagnostic criteria for
related lung diseases; (2) The factors of lung diseases were infection and sepsis;
2. Inclusion criteria of the control group: control 1: (1) Meeting the specific diagnostic
criteria for related lung diseases; (2) The factors of lung diseases were non-infectious
factors.
Control 2: Healthy children
3. Exclusion criteria of the test group: (1) Patients with hemodynamic instability Patients
with pulmonary hypertension;(2) Patients with congenital heart disease, congenital
genetic metabolic disease, epilepsy, acute and chronic renal insufficiency, nephrotic
syndrome, diabetes, et al.
4. The collection of clinical data includes: name, sex, age, hospitalization number, date
of hospitalization, main diagnosis, course of disease, main examination and test
results, medication, respiratory support, prognosis, etc.
5. Collect peripheral blood serum, sputum or alveolar lavage fluid samples for target
sequencing.
